https://orcid.org/0000-0002-1722-4807
References
- Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–726.
- Finsinger P, Grammatico S, Chisini M, et al. Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol. 2016;172(4):554–560.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
- Oertel M, Elsayad K, Kroeger KJ, et al. Impact of radiation dose on local control and survival in extramedullary head and neck plasmacytoma. Radiat Oncol. 2019;14(1):63.
- Tsang RW, Campbell BA, Goda JS, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;101(4):794–808.
- Barzenje DA, Kolstad A, Ghanima W, et al. Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: a population-based, single-center study with median follow-up of 13.7 years. Hematol Oncol. 2018;36(1):217–223.
- Katodritou E, Terpos E, Symeonidis AS, et al. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek Myeloma Study Group in 97 patients. Am J Hematol. 2014;89(8):803–808.
- Aviles A, Huerta-Guzman J, Delgado S, et al. Improved outcome in solitary bone plasmacytomata with combined therapy. Hematol Oncol. 1996;14(3):111–117.
- Mauro GP, Neffa PP, Villar RC, et al. Safety and feasibility analysis of a prospective trial on stereotactic body radiotherapy for solitary bone plasmacytoma. Acta Haematol. 2021;144(6):627–632.
- Ramsingh G, Mehan P, Morgensztern D, et al. Prognostic factors influencing survival in solitary plasmacytoma. Br J Haematol. 2009;145(4):540–542.
- Mignot F, Schernberg A, Arsene-Henry A, et al. Solitary plasmacytoma treated by lenalidomide–dexamethasone in combination with radiation therapy: clinical outcomes. Int J Radiat Oncol Biol Phys. 2020;106(3):589–596.
- Kayane Mheidly TM, Hunault M, Benboubker L, et al. Adjuvant chemotherapy in the treatment of solitary bone plasmacytoma. Blood. 2016;128(22):4514.
- Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10.
- Sharpley FA, Neffa P, Panitsas F, et al. Long-term clinical outcomes in a cohort of patients with solitary plasmacytoma treated in the modern era. PLOS One. 2019;14(7):e0219857.
- El-Fattah MA, Aboelmagd M, Elhamouly M. Clinical risk factors of plasmacytoma mortality: a US population-based study. Br J Haematol. 2017;179(1):161–162.
- Thumallapally N, Meshref A, Mousa M, et al. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17(1):13.
- Dimopoulos MA, Moulopoulos LA, Maniatis A, et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96(6):2037–2044.
- Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter rare cancer network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):210–217.
- Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.